Chronic Lyme disease, long-contentious, is becoming more mainstream in medicine, after Covid-19 showcased how an infection can leave people with lingering symptoms. 🔗 https://t.co/OdGnlH9A7m https://t.co/OEzZR5VvNg ...

Chronic Lyme disease, long-contentious, is becoming more mainstream in medicine, after Covid-19 showcased how an infection can leave people with lingering symptoms https://t.co/u69itxhLks ...

Chronic Lyme disease, long-contentious, is becoming more mainstream in medicine, after Covid-19 showcased how an infection can leave people with lingering symptoms https://t.co/ukLSx9fvcD ...

It's over 11% of US adults took medication for depression in 2023 and those numbers have only increased in the past 2 years. But what happens when a patient comes off anti-depressants. About 1 in six people will experience withdrawal symptoms such as nausea, dizziness, although others may have even more intense symptoms.That's where Altro, a new teaalth program comes in. They pair patients up with doctors and pharmacies to produce custom anti-depressants in tiny doses which will help ease up withdrawal of s ...

We are back now with a football legend opening up about his health. Barry Sanders played 10 seasons for the Detroit Lions and cemented his place as one of the greatest running backs of all time. Well, on Father's Day last year, Sanders suffered a heart attack and now he is opening up about his life-changing experience.In a new documentary by Amgen called The Making of a Heart Attack, here's a sneak peek. For me, it wasn't like a real strong pain. It was just like persistent like right in the middle.And that ...

Stopping antidepressants doesn’t lead to as many withdrawal symptoms as previously thought, according to a new study https://t.co/D73Jd6xekU ...

- [Speaker] For decades, the opioid crisis has defied standard treatments, but deep in the shadows of modern medicine lies a radical but effective alternative. Ibogaine is a powerful psychedelic, often described as miraculous by those who've tried it because of its remarkable ability to erase years of addiction and the agony of withdrawal in just one harrowing session. - It is a revolutionary breakthrough.- The success rate is staggering. - [Speaker] But ibogaine remains illegal in the US in part because it ...

Financial Data and Key Metrics Changes - The company reported revenue of approximately $4 million for Q1 2025, a decrease from $10 million in the same quarter of 2024, primarily due to a shift in focus towards internal and co-development programs [22][23] - The net loss for the quarter was roughly $46 million, compared to a loss of around $41 million in Q1 2024, resulting in a loss of CAD0.15 per share [24][25] - The company ended the quarter with approximately $630 million in cash and equivalents, along with $180 million in available committed government funding, totaling about $810 million in liquidity [21][27] Business Line Data and Key Metrics Changes - The company maintained a cumulative total of 16 molecules that have reached the clinic, with no new molecules advancing in the quarter [22] - The company initiated work on one partner-initiated program, bringing the cumulative total to 97 programs with downstream participation [21] Market Data and Key Metrics Changes - The market opportunity for ABCL635, targeting vasomotor symptoms associated with menopause, is estimated to exceed $2 billion in annual sales, with approximately 30% of women experiencing moderate to severe symptoms [9][10] Company Strategy and Development Direction - The company is focused on advancing its lead programs, ABCL635 and ABCL575, into clinical trials, with plans to complete the CTA process for both programs [18][19] - The company aims to transition from a platform company to a clinical-stage biotech, with over 20 internal and co-development programs in the pipeline [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the biology and differentiation of ABCL635, highlighting the unmet medical need for non-hormonal treatments for vasomotor symptoms [18] - The company plans to start Phase I studies for ABCL635 in Q3 2025, with key readouts expected in mid-2026 [18] Other Important Information - The company is investing in building clinical manufacturing capabilities, expected to be operational by the end of 2025 [27] - The company has received commitments for funding from the Government of Canada's Strategic Innovation Fund and the Government of British Columbia, which will support its GMP facility and internal pipeline advancement [27] Q&A Session Summary Question: What do you expect this asset needs to see in terms of Phase one data to capture a competitive edge? - Management indicated that they will look for safety data and important biomarker data, which will provide early signs of target engagement and efficacy [30][31] Question: What should we expect to see from the upcoming ABCL575 preclinical data? - Management stated that the preclinical data will include early animal work and PK analysis, with expectations for a superior dosing regimen [35] Question: Given the risk around translatability of NKTR engagement, is there a precedent that gives confidence? - Management noted preclinical data from nonhuman primates provides optimism, but emphasized caution in drug development [37][38] Question: How are you thinking about the next development candidates? - Management is looking for high conviction biology with large unmet medical needs and compelling differentiation, likely focusing on GPCR or ion channel targets [40][41] Question: Can you provide context on the pause of Novorok molecules in the clinic? - Management believes the pause is related to fundraising efforts by Novorok, which is common in the current environment [57] Question: Is there consideration for U.S.-based manufacturing redundancies? - Management confirmed that their current manufacturing facility in Canada supports their clinical trials, and they have not yet considered U.S.-based manufacturing [58][59]